Finance

Lists
ELVN:NASDAQ
Enliven Therapeutics Inc
40,98 $
+0,86%
(+0,35) 1D
41,10 $
+0,29% (+0,12)
Pre-market
Closed: 9 հոկ, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ELVN...
Open
41,00 $
High
42,06 $
Low
40,29 $
Mkt. cap
3,00 մլրդ
Avg. vol.
1,37 մլն
Volume
1,02 հզր
52-wk high
62,32 $
52-wk low
14,78 $
EPS
-1,67 $
Beta
0,24
Shares outstanding
73,27 մլն
No. of employees
67
Open
41,00 $
High
42,06 $
Low
40,29 $
Mkt. cap
3,00 մլրդ
Avg. vol.
1,37 մլն
Volume
1,02 հզր
52-wk high
62,32 $
52-wk low
14,78 $
EPS
-1,67 $
Beta
0,24
Shares outstanding
73,27 մլն
No. of employees
67
News stories
From web sources and news partners
About Enliven Therapeutics Inc
CEO-
Employees67
Founded2016
HeadquartersԲոուլդեր, Կոլորադո, Միացյալ Նահանգներ
Sector-
Analyst ratings
Based on 13 analysts giving stock ratings to ELVN in the past 3 months
Strong buy
Buy
13
Hold
0
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for ELVN in the last 3 months.
Highest
Current 40,98 $
82,00 $ (+100,10%)
Average
74,45 $ (+81,67%)
Lowest
68,00 $ (+65,93%)
Analyst
Recommendation
Action
Price target
Projected
Date
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
10/07/2026
Etzer Darout
Barclays
Buy
Maintained
78,00 $
+90,3%
10/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
10/06/2026
Sean Laaman
Morgan Stanley
Buy
Initiated
70,00 $
+70,8%
10/05/2026
Priyanka Grover
J.P. Morgan
Buy
Initiated
75,00 $
+83%
10/01/2026
Salim Syed
Mizuho Securities
Buy
Maintained
73,00 $
+78,1%
08/17/2026
Dara Azar
Stifel Nicolaus
Buy
Reiterated
82,00 $
+100,1%
08/13/2026
Sam Slutsky
LifeSci Capital
Buy
Reiterated
70,00 $
+70,8%
08/08/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
75,00 $
+83%
08/06/2026
Boris Peaker
JonesTrading
Buy
Reiterated
70,00 $
+70,8%
08/06/2026
Michael Schmidt
Guggenheim
Buy
Maintained
78,00 $
+90,3%
08/05/2026
Salveen Richter
Goldman Sachs
Buy
Reiterated
80,00 $
+95,2%
08/05/2026
Kaveri Pohlman
Clear Street
Buy
Reiterated
68,00 $
+65,9%
08/06/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
65,00 $
+58,6%
07/09/2026
Unknown Analyst
Jefferies
Buy
Maintained
59,00 $
+44%
06/15/2026
Soumit Roy
JonesTrading
Buy
Maintained
45,00 $
+9,8%
04/06/2026
Last report
05 օգս, 2026 թ.
Fiscal period
Q2 2026
-0,49 $ / -0,38 $
-29,80%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18,22 մլն
21,24 մլն
20,69 մլն
29,00 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,87 մլն
13,04 մլն
7,14 մլն
8,21 մլն
Operating expense
25,10 մլն
34,28 մլն
27,82 մլն
37,21 մլն
Total operating expenses
25,10 մլն
34,28 մլն
27,82 մլն
37,21 մլն
Operating income
-25,10 մլն
-34,28 մլն
-27,82 մլն
-37,21 մլն
Other non operating income
-
-
-
-8,00 հզր
EBT including unusual items
-20,15 մլն
-29,67 մլն
-23,63 մլն
-32,48 մլն
EBT excluding unusual items
-20,15 մլն
-29,67 մլն
-23,63 մլն
-32,48 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,15 մլն
-29,67 մլն
-23,63 մլն
-32,48 մլն
Net profit margin
-
-
-
-
Earnings per share
-0,32
-0,48
-0,38
-0,49
Interest and investment income
4,95 մլն
4,62 մլն
4,20 մլն
4,73 մլն
Interest expense
-
-
-
-
Net interest expenses
4,95 մլն
4,62 մլն
4,20 մլն
4,73 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-25,03 մլն
-34,24 մլն
-27,81 մլն
-37,20 մլն
Gain or loss from assets sale
-
106,00 հզր
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google Apps